Literature DB >> 1372100

Elevated hprt mutant frequency in circulating T-lymphocytes of xeroderma pigmentosum patients.

J Cole1, C F Arlett, P G Norris, G Stephens, A P Waugh, D M Beare, M H Green.   

Abstract

The mutant frequency to 6-thioguanine resistance in circulating T-lymphocytes from 10 xeroderma pigmentosum patients (including complementation groups D and G and XP variants) has been determined. A highly significantly elevated frequency was observed, compared to age-matched, non-smoking control donors (x 2.1-fold higher than the mutant frequency in normal control donors, adjusted for age and cloning efficiency, p less than 0.001). The mutant frequency of 5 XP heterozygotes was in the normal range, when age, smoking habit and log cloning efficiency were taken into account. A number of possible factors which may account for the elevated mutant frequency seen in the XP donors (including an elevated spontaneous mutation rate, UV mutagenesis of the T-cells as they pass through the skin, an effect of environmental mutagens such as tobacco smoke, or as a consequence of immune deficiency) are discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1372100     DOI: 10.1016/0921-8777(92)90078-h

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  4 in total

1.  Clinical heterogeneity within xeroderma pigmentosum associated with mutations in the DNA repair and transcription gene ERCC3.

Authors:  W Vermeulen; R J Scott; S Rodgers; H J Müller; J Cole; C F Arlett; W J Kleijer; D Bootsma; J H Hoeijmakers; G Weeda
Journal:  Am J Hum Genet       Date:  1994-02       Impact factor: 11.025

2.  Elevated levels of somatic mutation in a manifesting BRCA1 mutation carrier.

Authors:  Stephen G Grant; Rubina Das; Christina M Cerceo; Wendy S Rubinstein; Jean J Latimer
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

Review 3.  Future research directions for evaluating human genetic and cancer risk from environmental exposures.

Authors:  R J Albertini; J A Nicklas; J P O'Neill
Journal:  Environ Health Perspect       Date:  1996-05       Impact factor: 9.031

4.  Xeroderma pigmentosum variant: 5 years of tumour suppression by etretinate.

Authors:  J Berth-Jones; J Cole; A R Lehmann; C F Arlett; R A Graham-Brown
Journal:  J R Soc Med       Date:  1993-06       Impact factor: 18.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.